Middle East & Africa Sepsis Therapeutics Market Size & Outlook
Related Markets
MEA sepsis therapeutics market highlights
- The MEA sepsis therapeutics market generated a revenue of USD 128.9 million in 2024.
- The market is expected to grow at a CAGR of 5% from 2025 to 2030.
- In terms of segment, cephalosporin was the largest revenue generating drug class in 2024.
- Glycopeptide is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
| Market revenue in 2024 | USD 128.9 million |
| Market revenue in 2030 | USD 172.7 million |
| Growth rate | 5% (CAGR from 2025 to 2030) |
| Largest segment | Cephalosporin |
| Fastest growing segment | Glycopeptide |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cephalosporin, Aminoglycosides, Glycopeptide, Other Drug Class |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.3% of the global sepsis therapeutics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,526.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Sepsis Therapeutics Market Scope
Sepsis Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Aridis Pharmaceuticals | View profile | 11-50 | San Jose, California, United States, North America | http://aridispharma.com/ |
| Pfizer, Inc. | View profile | - | - | - |
| Eli Lilly and Company | View profile | - | - | - |
| La jolla Pharmaceutical | View profile | 101-250 | San Diego, California, United States, North America | https://www.lajollapharmaceutical.com |
| AstraZeneca PLC ADR | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| T2 Biosystems Inc | View profile | 113 | 101 Hartwell Avenue, Lexington, MA, United States, 02421 | https://www.t2biosystems.com |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Asahi Kasei Corp | View profile | 48897 | 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, Japan, 101-8101 | http://www.asahi-kasei.co.jp |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
Middle East & Africa sepsis therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sepsis therapeutics market will help companies and investors design strategic landscapes.
Cephalosporin was the largest segment with a revenue share of 63.38% in 2024. Horizon Databook has segmented the Middle East & Africa sepsis therapeutics market based on cephalosporin, aminoglycosides, glycopeptide, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Middle East & Africa sepsis therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa sepsis therapeutics market databook
-
Our clientele includes a mix of sepsis therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa sepsis therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa sepsis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA sepsis therapeutics market size, by country, 2018-2030 (US$M)
Middle East & Africa Sepsis Therapeutics Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
